<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin Zamora, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H709584814"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cytomegalovirus (CMV), a betaherpesvirus, is an important cause of morbidity and mortality in lung transplant recipients [<a href="#rid1">1</a>]. It is among the most common infections in lung transplant recipients, closely following bacterial pneumonia [<a href="#rid2">2,3</a>]. While the development and availability of potent antiviral agents have decreased CMV-related mortality, there is a growing body of evidence that the indirect effects of CMV may be equally important or even more important than its direct effects of tissue injury and infection [<a href="#rid3">3</a>]. CMV-induced immunosuppression may lead to infection with other opportunistic organisms. In addition, CMV infection and disease have been associated with acute and chronic rejection (chronic lung allograft dysfunction) [<a href="#rid4">4-6</a>]. The approach to the diagnosis and treatment of CMV infections in lung transplant recipients continues to evolve as molecular diagnostic techniques and antiviral therapies advance.</p><p>The epidemiology, clinical features, diagnosis, and treatment of CMV infection in lung transplant recipients will be discussed here. Prevention of CMV infection in lung transplant recipients as well as infectious complications due to pathogens other than CMV are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H410319"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Primary CMV infection is acquired through close physical contact involving direct inoculation with infected cells or body fluids. Following primary infection, CMV infection persists for life. Population studies document a gradual increase in CMV seropositivity through young adulthood. Although there is considerable variability, more than one half of adults in the United States have serologic evidence of previous infection. (See  <a class="medical medical_review" href="/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults"</a>.)</p><p>CMV infection following transplantation can be acquired in one of several ways [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Transmission from the donor organ from a CMV-seropositive donor</p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion of blood products from a CMV-seropositive blood donor</p><p class="bulletIndent1"><span class="glyph">●</span>Reactivation of latent infection in a seropositive recipient</p><p class="bulletIndent1"><span class="glyph">●</span>Close physical contact with a CMV-infected individual</p><p></p><p class="headingAnchor" id="H3610532073"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>CMV infection and disease are not synonymous terms; not all patients with infection develop overt clinical disease [<a href="#rid7">7-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV infection</strong> is characterized by virus isolation or detection of viral proteins (antigens) or nucleic acid in any body fluid or tissue specimen regardless of symptoms or signs. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV disease</strong> is characterized by evidence of CMV infection with attributable symptoms or signs; CMV disease may manifest as either a viral syndrome with fever, malaise, leukopenia, neutropenia, atypical lymphocytosis, and/or thrombocytopenia or as tissue-invasive disease. (See <a class="local">'Clinical manifestations'</a> below.)</p><p></p><p class="headingAnchor" id="H709584835"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3948402912"><span class="h2">Spectrum of illness</span><span class="headingEndMark"> — </span>CMV infection in the lung transplant recipient may range from asymptomatic viremia (CMV infection) to CMV disease manifested as a viral syndrome or as tissue-invasive disease, most commonly pneumonitis. (See <a class="local">'Definitions'</a> above.)</p><p>Most CMV-related illnesses occur in the early post-transplant period when immunosuppression is at its peak. Among lung transplant recipients not receiving antiviral prophylaxis, CMV-related illnesses typically occur within the first three months of transplant, with a mean time to viremia of 40 days post-transplantation [<a href="#rid10">10</a>]. The time to the onset of CMV infection and/or disease can be delayed in those receiving antiviral prophylaxis. Those at highest risk for CMV-related illness are CMV-seronegative recipients who receive allografts from CMV-seropositive donors. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H1533228166"><span class="h2">Asymptomatic viremia</span><span class="headingEndMark"> — </span>Asymptomatic viremia is among the most common clinical presentations of CMV infection post-transplant. Asymptomatic viremia is typically detected by routine CMV viral load monitoring post-transplantation. Strategies for viral load monitoring and interpretation of results are discussed separately. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p class="headingAnchor" id="H3041385200"><span class="h2">Symptomatic disease</span></p><p class="headingAnchor" id="H547798662"><span class="h3">CMV syndrome (symptomatic viremia)</span><span class="headingEndMark"> — </span>Patients with a CMV syndrome have evidence of clinical disease but without end-organ involvement [<a href="#rid8">8</a>]. Typical symptoms include fever, malaise, weakness, myalgias, and arthralgias. Many patients have leukopenia and/or thrombocytopenia that occur in the setting of viremia.</p><p>The following definition of probable CMV syndrome requires detection of CMV in blood (typically by nucleic acid testing) along with ≥2 of the following [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever ≥38°C (100.4°F) for ≥2 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New or increased malaise or new or increased fatigue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukopenia or neutropenia on two separate measurements at least 24 hours apart, defined as a white blood cell (WBC) count of &lt;3500 cells/mcL if the WBC count prior to the development of clinical symptoms was ≥4000 cells/mcL or a WBC decrease of &gt;20 percent if the WBC count prior to the development of clinical symptoms was &lt;4000 cells/mcL. The corresponding neutrophil counts are &lt;1500 cells/mcL or a decrease of &gt;20 percent if the neutrophil count before the onset of symptoms was &lt;1500 cells/mcL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical lymphocytosis of ≥5 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia defined as a platelet count of &lt;100,000 cells/mcL if the platelet count prior to the development of clinical symptoms was ≥115,000 cells/mcL or a decrease of &gt;20 percent if the platelet count prior to the development of clinical symptoms was &lt;115,000 cells/mcL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevation of transaminases to ≥2 times the upper limit of normal.</p><p></p><p class="headingAnchor" id="H2351055713"><span class="h3">Pneumonitis</span><span class="headingEndMark"> — </span>Pneumonitis is the most common presentation of tissue-invasive CMV disease in lung transplant recipients. Clinical features of CMV pneumonitis are nonspecific and include low-grade fever, shortness of breath, nonproductive cough, and changes in measured pulmonary function. Radiographic features are also nonspecific and varied, including patchy or diffuse ground-glass opacities, patchy consolidation, small nodular opacities, and combinations of these features  (<a class="graphic graphic_diagnosticimage graphicRef50696" href="/d/graphic/50696.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef65546" href="/d/graphic/65546.html" rel="external">image 2</a>) [<a href="#rid11">11-13</a>]. Less frequently reported findings include thickened bronchovascular bundles, tree-in-bud opacities, reticular opacities, and small pleural effusions [<a href="#rid11">11,12</a>].</p><p>Because the features of CMV pneumonitis and acute allograft rejection overlap, distinguishing these two disorders can be challenging. The timing of presentation can help. CMV disease rarely occurs within the first two weeks following transplantation and the mean time to development of pneumonitis following transplantation is 55 days among patients not taking CMV prophylaxis [<a href="#rid14">14</a>]. In contrast, acute rejection can occur within the first few weeks following transplantation, although its time course is variable. While this timeline serves a helpful rule of thumb, biopsy of the lung is generally needed to definitively distinguish these two disorders. (See <a class="local">'Pneumonitis'</a> below.)</p><p>CMV pneumonitis is a severe form of tissue-invasive disease in lung transplant recipients. In a study of 231 lung transplant recipients, five-year survival was significantly higher in patients who did not develop CMV pneumonitis during the first six months following transplantation compared with those who were treated for CMV pneumonitis during the first six months (71 versus 53 percent) [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1178311078"><span class="h3">Other tissue-invasive disease</span><span class="headingEndMark"> — </span>Other forms of tissue-invasive CMV disease, such as enteritis, hepatitis, and retinitis, are less common than pneumonitis in lung transplant recipients but do occur [<a href="#rid10">10,16</a>]. Clinical features of other tissue-invasive diseases are similar to those that occur in other patient populations. (See  <a class="medical medical_review" href="/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Organ-specific complications'</a>.)</p><p class="headingAnchor" id="H709588855"><span class="h2">Indirect effects</span><span class="headingEndMark"> — </span>In addition to the direct effects of CMV infection and disease, CMV has been associated with chronic rejection (chronic lung allograft dysfunction; previously termed bronchiolitis obliterans syndrome) in lung transplant recipients [<a href="#rid15">15,17-20</a>]. In one study, treated CMV pneumonitis that developed during the first six months after transplantation increased the risk for chronic lung allograft dysfunction (hazard ratio [HR] 2.19, 95% CI 1.36-3.51) and post-transplantation death (HR 1.89, 95% CI 1.11-3.23) [<a href="#rid15">15</a>]. In another study, the use of CMV prophylaxis resulted in a significant decrease in the rate of chronic lung allograft dysfunction following lung transplantation [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p>CMV has also been associated with acute rejection in renal and liver transplant recipients [<a href="#rid18">18,22,23</a>].</p><p>The immunomodulatory effects of CMV may predispose patients to several opportunistic infections, including those caused by <em>Aspergillus</em> species, <em>Pneumocystis jirovecii</em>, <em>Nocardia </em>species, and Epstein-Barr virus-associated post-transplant-associated lymphoproliferative disease [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H709584842"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The approach to diagnosis varies with the suspected clinical syndrome and site of infection. In general, quantitative polymerase chain reaction (PCR) is the preferred test for detecting CMV in blood [<a href="#rid9">9</a>]. Evidence of CMV infection at the affected site is required for the diagnosis of pneumonitis and other tissue-invasive CMV diseases [<a href="#rid9">9</a>].</p><p>Our approach to diagnosis is generally consistent with the 2018 international consensus guidelines on the management of CMV in solid organ transplantation [<a href="#rid9">9</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H3803710807"><span class="h2">Asymptomatic viremia</span><span class="headingEndMark"> — </span>The diagnosis of asymptomatic CMV viremia is typically made during routine CMV viral-load monitoring post-transplantation. Strategies for viral-load monitoring and interpretation of results are discussed separately. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p class="headingAnchor" id="H4055164841"><span class="h2">CMV syndrome</span><span class="headingEndMark"> — </span>For patients with suspected CMV syndrome (eg, fever, malaise, leukopenia, and/or lymphocytosis in the absence of end-organ disease), we generally obtain a quantitative PCR (ie, viral load) from plasma or whole blood for diagnosis. Because viral-load testing is very sensitive [<a href="#rid24">24,25</a>], assays vary among institutions, and the clinical features of CMV syndrome are nonspecific, interpreting results can be challenging.</p><p class="bulletIndent1"><span class="glyph">●</span>In general, an elevated viral load in a patient with a clinically compatible syndrome (in whom other causes seem unlikely) is considered diagnostic. However, the significance of very low viral loads (ie, detectable but not quantifiable viral loads or viral loads near the lower limit of the assay) is not certain. Thus, we weigh the clinical context heavily when deciding when to repeat the viral load for confirmation and/or starting antiviral treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A negative test result (eg, an undetectable viral load) is often sufficient to rule out CMV as the cause of a patient's symptoms. However, in some patients with tissue-invasive disease (particularly CMV enteritis), plasma and whole-blood viral loads can be undetectable despite CMV replication in tissue.</p><p></p><p>Although quantitative PCR has limitations, it is the test of choice for the diagnosis [<a href="#rid7">7,26,27</a>]. In general, a quantitative PCR assay that is calibrated to the World Health Organization (WHO) international standard (with results reported in international units/mL) should be used. Calibration to the international standard reduces some but not all variability among different assays and different institutional testing practices [<a href="#rid28">28,29</a>]. Because sample types (plasma versus whole blood), deoxyribonucleic acid (DNA) extraction techniques, and other factors still vary among testing centers, it is important to use the same assay while monitoring an individual patient over time.</p><p>The optimal sample type (ie, whole blood versus plasma) for quantitative PCR testing has not been determined. Both assays are used in clinical practice but are not interchangeable [<a href="#rid7">7,30</a>]. Whole-blood assays may be more sensitive that plasma assays, while plasma assays appear to be more specific. Because the amount of virus detected differs between sample types, neither the sample type nor the assay used should be changed when monitoring patients. (See  <a class="medical medical_review" href="/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection", section on 'Whole blood versus plasma'</a>.)</p><p>Historically, the CMV pp65 antigenemia assay was commonly used for the diagnosis of CMV syndrome, but this has now been largely supplanted by quantitative PCR. Serology should <strong>not</strong> be used to diagnose active CMV infection or disease in lung transplant recipients. (See  <a class="medical medical_review" href="/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection"</a> and  <a class="medical medical_review" href="/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection"</a>.)</p><p class="headingAnchor" id="H2067679022"><span class="h2">Pneumonitis</span><span class="headingEndMark"> — </span>For patients with suspected CMV pneumonitis, we obtain sampling from the lung in addition to quantitative PCR from blood [<a href="#rid31">31-33</a>]. When safe and feasible, we perform bronchoscopy with transbronchial biopsy for tissue diagnosis. The key reason for performing the biopsy is to distinguish CMV pneumonitis from allograft rejection. While the histologic features of these two disorders overlap, the presence of CMV inclusion bodies  (<a class="graphic graphic_diagnosticimage graphicRef65546" href="/d/graphic/65546.html" rel="external">image 2</a>) and/or CMV viral antigens (by immunohistochemistry or DNA hybridization) in lung tissue provides a definitive diagnosis of CMV pneumonitis [<a href="#rid9">9,34-37</a>].</p><p>When lung tissue cannot be obtained, a presumptive diagnosis can be made based on detection of the virus by PCR or culture in bronchoalveolar lavage (BAL) fluid or bronchial washings, provided that the clinical picture is compatible and other causes have been excluded [<a href="#rid9">9,38-42</a>]. However, caution should be taken when using this approach. Neither PCR nor culture can distinguish viral shedding from tissue-invasive disease. In addition, PCR has not been standardized for use on BAL fluid or bronchial washings.</p><p>To help corroborate the diagnosis of CMV pneumonitis, we generally obtain a peripheral quantitative PCR (eg, from whole blood or plasma). Elevated CMV viral loads are common among patients with CMV pneumonitis, but this finding alone is nonspecific and insufficient for diagnosis.</p><p>Additional detail on the diagnosis of CMV pneumonitis and the histopathologic findings associated with tissue-invasive CMV disease is provided separately. (See  <a class="medical medical_review" href="/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection", section on 'Tissue-invasive disease'</a> and  <a class="medical medical_review" href="/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection", section on 'Histopathology'</a>.)</p><p class="headingAnchor" id="H3248685098"><span class="h2">Other tissue-invasive disease</span><span class="headingEndMark"> — </span>Although other forms of tissue-invasive CMV disease (eg, enteritis/colitis) are less common than pneumonitis in lung transplant recipients, the approach to diagnosis is similar and requires evidence of CMV infection at the affected site in a patient with a compatible clinical picture. Elevated peripheral CMV viral loads are generally corroborative but can be negative even in the presence of active tissue-invasive disease. (See  <a class="medical medical_review" href="/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection", section on 'Testing based on type of disease'</a>.)</p><p class="headingAnchor" id="H3615537786"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H4128632612"><span class="h2">Pre-emptive therapy for asymptomatic viremia</span><span class="headingEndMark"> — </span>Most patients with asymptomatic CMV viremia require antiviral treatment. The rationale for treating patients with asymptomatic CMV viremia (ie, pre-emptive therapy) is to prevent the development of invasive disease and the potential indirect effects of CMV viremia, such as rejection.</p><p>The diagnosis of asymptomatic CMV viremia is typically made during routine CMV viral-load monitoring post-transplantation. Because viral load assays vary among institutions, the specific viral-load threshold that should trigger the need for treatment is typically determined by the individual transplant center [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients", section on 'Diagnostic tests'</a> and  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients", section on 'Pre-emptive therapy'</a>.)</p><p>When pre-emptive therapy is indicated, we generally use <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> 900 mg orally every 12 hours (adjusted for renal dysfunction). While on therapy, we monitor the viral load weekly or biweekly. We typically treat until the viral load is undetectable or less than the lower quantifiable limit of the assay (ie, &lt;200 international units/mL) on a single highly sensitive assay or until the viral load is undetectable on two consecutive samples when using less sensitive assays. (See <a class="local">'Monitoring on therapy'</a> below.)</p><p>Our treatment recommendations are largely consistent with the 2018 Transplantation Society international CMV consensus guidelines [<a href="#rid9">9</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H1923212271"><span class="h2">Treatment of symptomatic disease</span><span class="headingEndMark"> — </span>Treatment of symptomatic CMV disease generally involves both reduction of immunosuppression and antiviral therapy, typically with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> or intravenous (IV) <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> [<a href="#rid7">7,9,43,44</a>]. Our treatment recommendations are largely consistent with the 2018 Transplantation Society international CMV consensus guidelines [<a href="#rid9">9</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H702059837"><span class="h3">Reduction of immunosuppression</span><span class="headingEndMark"> — </span>Immunosuppression should be cautiously reduced (eg, holding or reducing the dose of immunosuppressive medications) in patients with CMV disease to promote the generation of CMV-specific immunity, when feasible [<a href="#rid7">7,45</a>]. The decision to reduce immunosuppression should be made on a case-by-case basis but should be considered most strongly in patients with moderate to severe disease, high viral loads, slow clinical or virologic response to antiviral treatment, ganciclovir-resistant CMV, and/or in those with a high net state of immunosuppression [<a href="#rid44">44,45</a>].</p><p class="headingAnchor" id="H3017248835"><span class="h3">Antiviral therapy</span><span class="headingEndMark"> — </span>For patients with symptomatic CMV disease, either oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> or IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> are the drugs of choice. We generally select between these two drugs based on disease severity. <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a>, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>, and oral ganciclovir should not be used for the treatment of CMV infection or disease.</p><p class="headingAnchor" id="H3190559827"><span class="h4">CMV syndrome</span><span class="headingEndMark"> — </span>Most patients with CMV syndrome (symptomatic viremia in the absence of tissue-invasive disease) have mild or moderate infections that can be treated with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>, provided that the patient is able to adequately tolerate and absorb oral medications. The standard treatment dose is 900 mg orally every 12 hours. For patients who cannot take medications or if there is clinical concern for rapidly progressive or severe disease, IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (5 mg/kg every 12 hours) should be used in place of valganciclovir. Dose adjustments may be needed for changes in renal function but should not be made to manage side effects such as leukopenia. (See <a class="local">'Monitoring on therapy'</a> below.)</p><p>Treatment duration is based on clinical and virologic response to therapy. In general, we monitor CMV viral loads weekly or biweekly on therapy. For patients whose viral loads are declining with treatment, we typically treat until a single viral load is undetectable or less than the lower quantifiable limit of the assay (when using a highly sensitive assay) or until two consecutive viral loads drawn ≥1 week apart are either undetectable (when using a less sensitive assay). The minimum duration of therapy is two weeks [<a href="#rid7">7</a>]. (See <a class="local">'Viral load'</a> below.)</p><p>Oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> appears to be equivalent to IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> for most transplant recipients with mild to moderate infections, such as CMV syndrome [<a href="#rid7">7,46</a>]. In addition, use of an oral antiviral agent for initial treatment may reduce hospital stays and any adverse events associated with IV therapy. In the valcyte in CMV disease treatment of solid organ recipients (VICTOR) trial, 321 solid organ transplant recipients with non-life-threatening CMV disease were randomized to either oral valganciclovir (900 mg twice daily) or IV ganciclovir (5 mg/kg IV twice daily) [<a href="#rid46">46</a>]. Both groups continued therapy for 21 days before switching to valganciclovir 900 mg once daily for an additional 28 days. Forty-eight percent of patients had a CMV syndrome and 49 percent had CMV disease. The primary endpoint was clearance of CMV viremia at day 21 of therapy, which was achieved in 45 percent of those receiving valganciclovir and 48 percent of those receiving ganciclovir. Clinical resolution of CMV disease was a secondary endpoint and was achieved in 77 percent of those receiving valganciclovir and 80 percent of those receiving ganciclovir. One year following treatment, there were no differences in clinical or viral eradication of CMV disease or in incidence of ganciclovir resistance between the patients who received valganciclovir and those who received ganciclovir [<a href="#rid47">47</a>]. Of note, lung transplant recipients were a minority (6 percent) of the solid organ transplant recipients evaluated. Thus, we do not assume that oral valganciclovir and IV ganciclovir are equivalent for the treatment of more severe CMV disease in lung transplant recipients, particularly for pneumonitis, which involves the allograft.</p><p class="headingAnchor" id="H3999898098"><span class="h4">Pneumonitis and tissue-invasive disease</span><span class="headingEndMark"> — </span>We treat lung transplant recipients with CMV pneumonitis with IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> 5 mg/kg IV every 12 hours, with dose adjustment for renal dysfunction, to ensure maximum bioavailability. IV ganciclovir can be transitioned to oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> once the patient has demonstrated clear clinical improvement, viral loads are down-trending, and the patient can tolerate/absorb oral medications. While treating with either ganciclovir or valganciclovir, we monitor the serum creatinine at regular intervals in case dose adjustment is needed. (See <a class="local">'Monitoring on therapy'</a> below.)</p><p>As with other forms of CMV disease, treatment duration for pneumonitis is based on clinical and virologic response to therapy. In general, we monitor CMV viral loads weekly or biweekly while on therapy. For patients whose viral loads are declining with treatment, we typically treat until a single viral load is undetectable or less than the lower quantifiable limit of the assay (when using a highly sensitive assay) or until two consecutive viral loads drawn ≥1 week apart are either undetectable (when using a less sensitive assay). The minimum duration of therapy is two weeks [<a href="#rid7">7</a>]. (See <a class="local">'Viral load'</a> below.)</p><p>The addition of <a class="drug drug_general" data-topicid="9315" href="/d/drug information/9315.html" rel="external">cytomegalovirus immune globulin</a> (CytoGam) to antiviral therapy might theoretically improve treatment response and, while this approach is used by some experts, data supporting its use are limited and we do not routinely employ this approach.</p><p class="headingAnchor" id="H2534838402"><span class="h3">Monitoring on therapy</span></p><p class="headingAnchor" id="H2804422761"><span class="h4">Viral load</span><span class="headingEndMark"> — </span>We generally monitor CMV viral loads weekly or biweekly while on therapy to assess response to treatment and guide duration of therapy. Because there is variability among assays, we use the same quantitative PCR assay each time the viral load is measured. (See <a class="local">'CMV syndrome'</a> above and  <a class="medical medical_review" href="/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection", section on 'Molecular assays'</a>.)</p><p>During the first week of therapy, the viral load may rise (particularly in heavily immunosuppressed patients) but should fall steadily thereafter [<a href="#rid7">7,48</a>]. For patients whose viral loads continue to rise following the first week of therapy or for patients whose viral loads plateau or slowly decline, we consider the possibility of <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> resistance. (See <a class="local">'Ganciclovir resistance'</a> below.)</p><p>For patients whose viral loads are declining with treatment, we typically treat until a single viral load is undetectable or less than the lower quantifiable limit of the assay (when using a highly sensitive assay) or until two consecutive viral loads drawn ≥1 week apart are either undetectable (when using a less sensitive assay). The minimum duration of therapy is two weeks [<a href="#rid7">7</a>]. However, most patients will require longer treatment courses, particularly those with severe tissue-invasive disease, high initial viral loads, or those who are heavily immunocompromised.</p><p>There has been some interest in using CMV-specific immune monitoring assays to help guide the duration of treatment. At this time, there are insufficient data to support the use of these routinely, but further research is being performed to help define whether these assays can help inform the duration of treatment [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients", section on 'CMV-specific immunity'</a>.)</p><p class="headingAnchor" id="H1687946256"><span class="h4">Renal function</span><span class="headingEndMark"> — </span>In addition to monitoring CMV viral loads weekly while on therapy, we also check a serum creatinine at routine intervals (eg, weekly or biweekly) to help guide appropriate antiviral dosing. Subtherapeutic dosing raises the risk of developing <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> resistance while on therapy. Supratherapeutic dosing increases the chance of drug-related toxicities.</p><p class="headingAnchor" id="H1135521137"><span class="h4">Blood cell counts</span><span class="headingEndMark"> — </span>Bone marrow suppression, in particular leukopenia, appears to be the most significant and common toxicity associated with <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> and <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> use. Given this risk, we generally check a complete blood count weekly while patients are on therapy.</p><p>If leukopenia occurs while on therapy, antiviral dosing should not be decreased because of the risk of promoting drug resistance [<a href="#rid7">7</a>]. Evaluation for other causes (eg, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> toxicity, worsening/persistent CMV infection) should be pursued. If <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> or <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> is determined to be an important cause or contributor, the addition of granulocyte colony stimulating factor should be considered before discontinuing or changing antiviral therapy. (See  <a class="medical medical_review" href="/d/html/8342.html" rel="external">"Ganciclovir and valganciclovir: An overview", section on 'Bone marrow suppression'</a>.)</p><p class="headingAnchor" id="H451910063"><span class="h2">Ganciclovir resistance</span><span class="headingEndMark"> — </span>Resistance to <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> should be considered in recipients who fail to improve clinically and/or virologically after two weeks of adequate doses of antiviral therapy or who have recurrent relapses following treatment. Factors that raise the likelihood of ganciclovir resistance include prolonged antiviral use, lack of prior CMV immunity (CMV D+/R-), and inadequate antiviral drug selection or dosing (eg, treatment with oral ganciclovir or subtherapeutic dosing of IV ganciclovir or <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>) [<a href="#rid9">9,50-52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance testing</strong> – Genotypic resistance testing should be performed in patients with suspected <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> resistance [<a href="#rid7">7,9,43,53-56</a>]. In patients who have been treated with ganciclovir, the most common mutations are UL97 phosphotransferase mutations [<a href="#rid9">9,51,56,57</a>]. Certain UL97 mutations confer ganciclovir resistance by diminishing the enzyme's ability to phosphorylate GCV, a modification needed for antiviral activity [<a href="#rid58">58,59</a>]. The degree of ganciclovir resistance conferred varies among UL97 mutations. In most cases, treatment with an alternate antiviral agent is needed; in a minority of cases, resistance can be overcome with higher dose ganciclovir.</p><p></p><p class="bulletIndent1">UL54 DNA polymerase mutations may occur, usually as second-step mutations in patients who already have a UL97 mutation. UL54 mutations rarely are the first mutation to occur, and alone are not always associated with clinical antiviral resistance. CMV isolates possessing both UL97 and UL54 mutations often have high-level <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> resistance [<a href="#rid10">10,60-62</a>]. The resistance conferred by UL54 mutations cannot be overcome by increasing the dose of ganciclovir. UL54 DNA polymerase mutations confer various combinations of resistance to ganciclovir, <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>, and/or <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Data on the treatment of ganciclovir-resistant CMV infection are mixed and limited [<a href="#rid9">9,63-68</a>], and the approach to treatment varies based on disease severity, viral gene mutation, antiviral drug availability and safety profile, and host immune status.</p><p></p><p>Reduction of immunosuppression is particularly important in patients with resistant CMV disease [<a href="#rid7">7</a>]. Although the approach to reducing immunosuppression should be individualized, switching the immunosuppressive regimen to one that includes an mTOR inhibitor (eg, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>) can be considered because of the reportedly lower risk of CMV disease in patients receiving mTOR inhibitors [<a href="#rid69">69</a>].</p><p>In patients with severe disease and/or a substantial degree of immunosuppression, we typically use <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> 60 mg/kg IV every 8 hours (or 90 mg/kg IV every 12 hours), with adjustment for renal dysfunction [<a href="#rid70">70</a>]. It is important to note that nephrotoxicity is common when foscarnet is given in combination with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. Electrolyte disturbances are also common with foscarnet. An alternative to foscarnet is <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>, but there is less clinical experience with this agent for treating resistant CMV infection, and its use is limited by the potential for severe nephrotoxicity. (See  <a class="medical medical_review" href="/d/html/8288.html" rel="external">"Foscarnet: An overview"</a> and  <a class="medical medical_review" href="/d/html/8297.html" rel="external">"Cidofovir: An overview"</a>.)</p><p>In patients treated empirically for presumed ganciclovir-resistant CMV, the regimen should be adjusted as indicated based upon the results of genotypic resistance testing. UL97 mutations that confer low-level <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> resistance (less than twofold; eg, C592G mutation) may respond to an increase in the dose of IV ganciclovir up to 10 mg/kg IV every 12 hours (twice the US Food and Drug Administration [FDA]-approved dose), with adjustment for renal dysfunction [<a href="#rid7">7,9,64</a>].</p><p>Some experts have used <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> and <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> in combination for the treatment of ganciclovir-resistant CMV disease [<a href="#rid63">63</a>], but it is unclear whether there is benefit to this approach. <a class="drug drug_general" data-topicid="134463" href="/d/drug information/134463.html" rel="external">Maribavir</a>, benzimidazole antiviral agent, is a potential option for salvage treatment, but efficacy data for these agents in lung transplant recipients are mixed and limited [<a href="#rid7">7,44,68,71-74</a>]. While its toxicity profile is favorable (no bone marrow or renal toxicity), resistance has been reported to emerge during therapy [<a href="#rid75">75,76</a>]. </p><p><a class="drug drug_general" data-topicid="115632" href="/d/drug information/115632.html" rel="external">Letermovir</a>, a viral terminase inhibitor, is approved by the FDA for CMV prevention in allogeneic hematopoietic stem cell transplant (HCT) recipients and kidney transplant recipients [<a href="#rid77">77</a>]. Although letermovir has been reported to successfully treat ganciclovir-resistant CMV disease in a few lung transplantation recipients [<a href="#rid67">67,78,79</a>], it is not approved for this indication, optimal dosing has not yet been determined, and resistance can emerge while on therapy [<a href="#rid80">80</a>]. Letermovir is not recommended for treatment of ganciclovir-resistant CMV due to its low barrier to resistance. Evidence supporting the use of letermovir in other populations is discussed separately. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'CMV prevention'</a>.) </p><p>Experimental agents include <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a>, an immunosuppressive agent [<a href="#rid81">81-83</a>], and <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a>, an antimalaria drug [<a href="#rid84">84,85</a>]. Both have some in vitro activity against CMV, but further study is needed before either agent can be recommended.</p><p class="headingAnchor" id="H22545072"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H1481661922"><span class="h2">Primary prophylaxis</span><span class="headingEndMark"> — </span>CMV disease is associated with increased mortality rates among solid organ transplant recipients, and the use of antiviral prophylaxis against CMV is associated with a reduction in all-cause mortality after transplantation [<a href="#rid10">10,23,86-90</a>]. Methods to prevent CMV infection and disease following transplantation, including universal prophylaxis and pre-emptive therapy, are discussed separately. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p class="headingAnchor" id="H46966547"><span class="h2">Secondary prophylaxis</span><span class="headingEndMark"> — </span>Secondary prophylaxis (ie, continuing antiviral medications at prophylactic doses after completion of treatment for symptomatic disease) has not been associated with lower recurrence rates and is not routinely recommended [<a href="#rid7">7,91</a>].</p><p class="headingAnchor" id="H545638783"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109354.html" rel="external">"Society guideline links: Cytomegalovirus in solid organ transplant recipients"</a>.)</p><p class="headingAnchor" id="H10699071"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83958.html" rel="external">"Patient education: Cytomegalovirus (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H709584940"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Cytomegalovirus (CMV) is an important cause of morbidity and mortality in lung transplant recipients. CMV infection is characterized by virus isolation or detection of viral proteins (antigens) or nucleic acid in any body fluid or tissue specimen regardless of symptoms or signs. CMV disease refers to CMV infection with attributable symptoms or signs. (See <a class="local">'Introduction'</a> above and <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of illness</strong> – The spectrum of illness associated with CMV ranges from asymptomatic viremia to severe tissue-invasive disease. CMV syndrome and pneumonitis are among the most common manifestations in lung transplant recipients. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV syndrome</strong> – CMV syndrome refers to symptomatic viremia without evidence of tissue-invasive disease. The signs and symptoms that most commonly accompany viremia include fever, malaise, leukopenia, neutropenia, atypical lymphocytosis, and/or thrombocytopenia. (See <a class="local">'CMV syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumonitis</strong> – Clinical features of CMV pneumonitis are nonspecific and include low-grade fever, shortness of breath, nonproductive cough, and changes in measured pulmonary function. Because these features overlap with acute allograft rejection, distinguishing these two disorders can be challenging and biopsy is typically needed for diagnosis. (See <a class="local">'Pneumonitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The approach to diagnosis varies with the suspected clinical syndrome and site of infection. In general, CMV quantitative polymerase chain reaction (ie, viral-load testing) is the preferred test for detecting viremia. Evidence of CMV infection at the affected site is required for the diagnosis of pneumonitis and other tissue-invasive CMV diseases. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-emptive therapy for asymptomatic viremia</strong> – Most lung transplant recipients with asymptomatic CMV viremia should be given pre-emptive antiviral therapy to prevent the development of symptomatic and/or invasive disease as well as any potential indirect effects of CMV viremia, such as rejection. The viral load cut-off for which antiviral treatment should be given varies among institutions. When therapy is indicated, we typically use oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> 900 mg orally every 12 hours, adjusted for renal dysfunction. (See <a class="local">'Pre-emptive therapy for asymptomatic viremia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of symptomatic disease</strong> – For lung transplant recipients with symptomatic CMV disease, we generally reduce immunosuppression (when feasible) and recommend treatment with antiviral therapy. Typically, we use either oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> or intravenous (IV) <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>, depending on the severity of illness. (See <a class="local">'Treatment of symptomatic disease'</a> above and <a class="local">'Reduction of immunosuppression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of CMV syndrome</strong> – For most patients with CMV syndrome, we suggest treatment with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> (900 mg orally every 12 hours, adjusted for renal dysfunction) rather than IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>, provided that the patient is able to adequately tolerate and absorb oral medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Patients with CMV syndrome typically have mild to moderate infections, and clinical outcomes are similar when comparing IV ganciclovir with oral valganciclovir in solid organ transplant recipients. (See <a class="local">'CMV syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of pneumonitis or other tissue-invasive disease</strong> – We generally consider lung transplant recipients with pneumonitis or other tissue-invasive disease to have severe infection and recommend treatment with IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> 5 mg/kg IV every 12 hours over oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). IV ganciclovir can be transitioned to oral valganciclovir once the patient has demonstrated clear clinical improvement, viral loads are down-trending, and the patient can tolerate/absorb oral medications. Some experts give <a class="drug drug_general" data-topicid="9315" href="/d/drug information/9315.html" rel="external">CMV immune globulin</a> (CytoGam) in addition to antiviral therapy, but data supporting this approach are limited. (See <a class="local">'Pneumonitis and tissue-invasive disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – Treatment duration is based on clinical and virologic response to therapy. In general, we monitor CMV viral loads weekly or biweekly on therapy. We treat until the patient's symptoms have resolved and the viral load is undetectable or less than the lower quantifiable limit of the assay (when using a highly sensitive assay). The minimum duration of therapy is two weeks, but courses are frequently longer. (See <a class="local">'Viral load'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring on therapy</strong> – For patients being treated with <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> or <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>, we check a serum creatinine at regular intervals to help guide appropriate antiviral dosing. We also routinely check a complete blood count to monitor for bone marrow suppression. (See <a class="local">'Monitoring on therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">Ganciclovir</a><strong> resistance</strong> – For patients whose viral loads fail to decline while on therapy, we test for ganciclovir resistance. For most patients with confirmed ganciclovir resistance, we suggest <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Foscarnet should be dosed at 60 mg/kg IV every 8 hours (or 90 mg/kg IV every 12 hours), with dose adjustment for renal insufficiency and close monitoring for associated drug toxicities. (See <a class="local">'Ganciclovir resistance'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17:357.</a></li><li><a class="nounderline abstract_t">Balfour HH Jr. Cytomegalovirus: the troll of transplantation. Arch Intern Med 1979; 139:279.</a></li><li><a class="nounderline abstract_t">Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4:1219.</a></li><li><a class="nounderline abstract_t">Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297.</a></li><li><a class="nounderline abstract_t">Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21:271.</a></li><li><a class="nounderline abstract_t">Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170:1120.</a></li><li><a class="nounderline abstract_t">Razonable RR, Humar A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:93.</a></li><li><a class="nounderline abstract_t">Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis 2017; 64:87.</a></li><li><a class="nounderline abstract_t">Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 2018; 102:900.</a></li><li class="breakAll">Razonable RR, Limaye RR. Cytomegalovirus infection after solid organ transplantation. In: Transplant Infections, 3rd ed, Bowden RA, Ljungman P, Snydman DR (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. p.328.</li><li><a class="nounderline abstract_t">Franquet T, Lee KS, Müller NL. Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol 2003; 181:1059.</a></li><li class="breakAll">Webb WR, Muller NL, Naidich DP. Infections. In: High-resolution CT of the Lung, Lippincott Williams and Wilkins, Philadelphia 2009. p.415.</li><li><a class="nounderline abstract_t">Kang EY, Patz EF Jr, Müller NL. Cytomegalovirus pneumonia in transplant patients: CT findings. J Comput Assist Tomogr 1996; 20:295.</a></li><li><a class="nounderline abstract_t">Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993; 147:1017.</a></li><li><a class="nounderline abstract_t">Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181:1391.</a></li><li class="breakAll">Gavalda J, Roman A, Pahissa A. Risks and epidemiology of infections after lung or heart-lung transplantation. In: Transplant Infections, 3rd ed, Bowden RA, Ljungman P, Snydman DR (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. p.114.</li><li><a class="nounderline abstract_t">Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11:2190.</a></li><li><a class="nounderline abstract_t">Hakimi Z, Aballéa S, Ferchichi S, et al. Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting. Transpl Infect Dis 2017; 19.</a></li><li><a class="nounderline abstract_t">Stern M, Hirsch H, Cusini A, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014; 98:1013.</a></li><li><a class="nounderline abstract_t">Peghin M, Hirsch HH, Len Ó, et al. Epidemiology and Immediate Indirect Effects of Respiratory Viruses in Lung Transplant Recipients: A 5-Year Prospective Study. Am J Transplant 2017; 17:1304.</a></li><li><a class="nounderline abstract_t">Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46:831.</a></li><li><a class="nounderline abstract_t">Rosen HR, Corless CL, Rabkin J, Chou S. Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation 1998; 66:1627.</a></li><li><a class="nounderline abstract_t">Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46:840.</a></li><li><a class="nounderline abstract_t">Barber L, Egan JJ, Lomax J, et al. A prospective study of a quantitative PCR ELISA assay for the diagnosis of CMV pneumonia in lung and heart-transplant recipients. J Heart Lung Transplant 2000; 19:771.</a></li><li><a class="nounderline abstract_t">Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev 2013; 26:703.</a></li><li><a class="nounderline abstract_t">Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis 2012; 54:1793.</a></li><li><a class="nounderline abstract_t">Caliendo AM. The long road toward standardization of viral load testing for cytomegalovirus. Clin Infect Dis 2013; 56:374.</a></li><li><a class="nounderline abstract_t">Hayden RT, Sun Y, Tang L, et al. Progress in Quantitative Viral Load Testing: Variability and Impact of the WHO Quantitative International Standards. J Clin Microbiol 2017; 55:423.</a></li><li><a class="nounderline abstract_t">Jones S, Webb EM, Barry CP, et al. Commutability of Cytomegalovirus WHO International Standard in Different Matrices. J Clin Microbiol 2016; 54:1512.</a></li><li><a class="nounderline abstract_t">Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011; 91:231.</a></li><li><a class="nounderline abstract_t">Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102:1049.</a></li><li><a class="nounderline abstract_t">Clelland C, Higenbottam T, Stewart S, et al. Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor. Am Rev Respir Dis 1993; 147:1386.</a></li><li><a class="nounderline abstract_t">Paradis IL, Duncan SR, Dauber JH, et al. Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation. J Heart Lung Transplant 1992; 11:S232.</a></li><li><a class="nounderline abstract_t">Sibley RK, Berry GJ, Tazelaar HD, et al. The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant 1993; 12:308.</a></li><li><a class="nounderline abstract_t">Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15:1.</a></li><li><a class="nounderline abstract_t">Tazelaar HD. Perivascular inflammation in pulmonary infections: implications for the diagnosis of lung rejection. J Heart Lung Transplant 1991; 10:437.</a></li><li><a class="nounderline abstract_t">Nakhleh RE, Bolman RM 3rd, Henke CA, Hertz MI. Lung transplant pathology. A comparative study of pulmonary acute rejection and cytomegaloviral infection. Am J Surg Pathol 1991; 15:1197.</a></li><li><a class="nounderline abstract_t">Chemaly RF, Yen-Lieberman B, Castilla EA, et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol 2004; 42:2168.</a></li><li><a class="nounderline abstract_t">Riise GC, Andersson R, Bergström T, et al. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest 2000; 118:1653.</a></li><li><a class="nounderline abstract_t">Westall GP, Michaelides A, Williams TJ, et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190:1076.</a></li><li><a class="nounderline abstract_t">Gerna G, Lilleri D, Rognoni V, et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009; 9:1142.</a></li><li><a class="nounderline abstract_t">Lodding IP, Schultz HH, Jensen JU, et al. Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia. Transplantation 2018; 102:326.</a></li><li><a class="nounderline abstract_t">Zamora MR, Davis RD, Leonard C, CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005; 80:157.</a></li><li><a class="nounderline abstract_t">Kotton CN. CMV: Prevention, Diagnosis and Therapy. Am J Transplant 2013; 13 Suppl 3:24.</a></li><li><a class="nounderline abstract_t">Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012; 14:633.</a></li><li><a class="nounderline abstract_t">Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106.</a></li><li><a class="nounderline abstract_t">Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9:1205.</a></li><li><a class="nounderline abstract_t">Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97:867.</a></li><li><a class="nounderline abstract_t">Westall GP, Cristiano Y, Levvey BJ, et al. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation. Transplantation 2019; 103:1005.</a></li><li><a class="nounderline abstract_t">Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185:20.</a></li><li><a class="nounderline abstract_t">Fisher CE, Knudsen JL, Lease ED, et al. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. Clin Infect Dis 2017; 65:57.</a></li><li><a class="nounderline abstract_t">Khurana MP, Lodding IP, Mocroft A, et al. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. Open Forum Infect Dis 2019; 6:ofz215.</a></li><li><a class="nounderline abstract_t">Kruger RM, Shannon WD, Arens MQ, et al. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999; 68:1272.</a></li><li><a class="nounderline abstract_t">Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21:1274.</a></li><li><a class="nounderline abstract_t">Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689.</a></li><li><a class="nounderline abstract_t">Le Page AK, Jager MM, Iwasenko JM, et al. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013; 56:1018.</a></li><li><a class="nounderline abstract_t">Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873.</a></li><li><a class="nounderline abstract_t">Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011; 24:605.</a></li><li><a class="nounderline abstract_t">Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 2009; 19:215.</a></li><li><a class="nounderline abstract_t">Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005; 77:425.</a></li><li><a class="nounderline abstract_t">Chou S, Marousek GI, Van Wechel LC, et al. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007; 51:4160.</a></li><li><a class="nounderline abstract_t">Smith IL, Cherrington JM, Jiles RE, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69.</a></li><li><a class="nounderline abstract_t">Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002; 34:1337.</a></li><li><a class="nounderline abstract_t">West P, Schmiedeskamp M, Neeley H, et al. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transpl Infect Dis 2008; 10:129.</a></li><li><a class="nounderline abstract_t">Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70:965.</a></li><li><a class="nounderline abstract_t">Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22:162.</a></li><li><a class="nounderline abstract_t">Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11:1079.</a></li><li><a class="nounderline abstract_t">Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. Clin Infect Dis 2019; 68:1255.</a></li><li><a class="nounderline abstract_t">Strueber M, Warnecke G, Fuge J, et al. Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial. Am J Transplant 2016; 16:3171.</a></li><li><a class="nounderline abstract_t">Pierce B, Richardson CL, Lacloche L, et al. Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study. Transpl Infect Dis 2018; 20:e12852.</a></li><li><a class="nounderline abstract_t">Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010; 12:489.</a></li><li><a class="nounderline abstract_t">Alain S, Revest M, Veyer D, et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc 2013; 45:1603.</a></li><li><a class="nounderline abstract_t">Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol 2011; 1:548.</a></li><li><a class="nounderline abstract_t">Haidar G, Singh N. Viral infections in solid organ transplant recipients: novel updates and a review of the classics. Curr Opin Infect Dis 2017; 30:579.</a></li><li><a class="nounderline abstract_t">Avery RK, Alain S, Alexander BD, et al. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clin Infect Dis 2022; 75:690.</a></li><li><a class="nounderline abstract_t">Chou S, Song K, Wu J, et al. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. J Infect Dis 2022; 226:576.</a></li><li class="breakAll">US Food and Drug Administration. PREVYMIS (letermovir) Tablets and PREVYMIS (letermovir) Injection https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000TOC.cfm (Accessed on February 09, 2021).</li><li><a class="nounderline abstract_t">Veit T, Munker D, Kauke T, et al. Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients. Transplantation 2020; 104:410.</a></li><li><a class="nounderline abstract_t">Veit T, Munker D, Barton J, et al. Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study. Am J Transplant 2021; 21:3449.</a></li><li><a class="nounderline abstract_t">Cherrier L, Nasar A, Goodlet KJ, et al. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant 2018; 18:3060.</a></li><li><a class="nounderline abstract_t">Levi ME, Mandava N, Chan LK, et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8:38.</a></li><li><a class="nounderline abstract_t">Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004; 34:1071.</a></li><li><a class="nounderline abstract_t">Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010; 90:419.</a></li><li><a class="nounderline abstract_t">Wolf DG, Shimoni A, Resnick IB, et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011; 90:183.</a></li><li><a class="nounderline abstract_t">Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46:1455.</a></li><li><a class="nounderline abstract_t">Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78:1390.</a></li><li><a class="nounderline abstract_t">Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81:1645.</a></li><li><a class="nounderline abstract_t">Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105.</a></li><li><a class="nounderline abstract_t">Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870.</a></li><li><a class="nounderline abstract_t">Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43:869.</a></li><li><a class="nounderline abstract_t">Eid AJ, Arthurs SK, Deziel PJ, et al. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010; 10:157.</a></li></ol></div><div id="topicVersionRevision">Topic 15396 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241082" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/218511" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cytomegalovirus: the troll of transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15268722" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cytomegalovirus and lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897517" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834356" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk factors for bronchiolitis obliterans: a systematic review of recent publications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297275" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465003" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cytomegalovirus in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27682069" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596116" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596116" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500230" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500230" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606241" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cytomegalovirus pneumonia in transplant patients: CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8385429" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167845" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167845" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21794087" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28599091" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24837540" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27615811" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epidemiology and Immediate Indirect Effects of Respiratory Viruses in Lung Transplant Recipients: A 5-Year Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18269330" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9884250" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association of cytomegalovirus genotype with graft rejection after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260785" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10967271" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A prospective study of a quantitative PCR ELISA assay for the diagnosis of CMV pneumonia in lung and heart-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092851" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412060" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23097589" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The long road toward standardization of viral load testing for cytomegalovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27852673" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Progress in Quantitative Viral Load Testing: Variability and Impact of the WHO Quantitative International Standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27030491" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Commutability of Cytomegalovirus WHO International Standard in Different Matrices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21048530" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327662" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8503549" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1325184" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8476904" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The role of transbronchial biopsies in the management of lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8820078" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649636" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Perivascular inflammation in pulmonary infections: implications for the diagnosis of lung rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1660677" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Lung transplant pathology. A comparative study of pulmonary acute rejection and cytomegaloviral infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131185" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115455" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319856" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422339" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28846557" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16041258" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23347212" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : CMV: Prevention, Diagnosis and Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22992839" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17640310" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422345" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159510" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30247316" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756977" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369203" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31211159" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573063" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490272" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20930070" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antiviral drug resistance of human cytomegalovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23243176" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728878" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Human cytomegalovirus resistance to antiviral drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001948" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The biology of cytomegalovirus drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19434630" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173018" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709468" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207351" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981729" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17605740" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20481654" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : New developments in the management of cytomegalovirus infection after solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339135" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521474" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30329038" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27104933" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29380479" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20682012" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23726629" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Maribavir use in practice for cytomegalovirus infection in French transplantation centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22162744" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Progress in the development of new therapies for herpesvirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28984642" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Viral infections in solid organ transplant recipients: novel updates and a review of the classics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34864943" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32726419" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32726419" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31385924" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34118118" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30286286" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623819" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489872" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20683281" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21443904" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419454" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548980" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794529" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15964447" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16365468" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941368" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889123" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
